devoted to providing transplants to patients from outside a country undermine the country's ability to provide transplant services for its own population." 1 Thus, for transplant centers there is a financial incentive to transplanting NCNRs.
Over time, there have been different policies dictating formal (or informal) caps on the number of NCNR liver transplant recipients at a particular transplant center in an attempt to ensure equal distribution of organs. In 1994, the "5% rule" was established, which set the threshold at which transplant centers would be audited for their rate of NCNR liver transplants; thus, if more than 5% of a center's DDLT recipients were foreign nationals, it would trigger a formal review. In March 2012, the Organ Procurement and Transplantation Network (OPTN) restructured its citizenship classifications in order to better understand and track those traveling to the US for transplantation. 4 The term "nonresident aliens (NRAs)" was replaced with two new categories: NCNRs (noncitizens/nonresidents in the United
States for reasons other than a transplant) and NCNRtx (noncitizens/ nonresidents in the US specifically for the purpose of transplant). 4 In September 2012, OPTN Policy 17 removed the 5% audit trigger and instead required transplant centers report the citizenship and residency status of all patients undergoing transplantation 5 in an attempt to increase the transparency of transplantation rates in foreign nationals.
Although there has been much work done recently in terms of looking at the disparities in access to liver transplantation based on socioeconomic, racial, and geographic factors, 6 there are almost no data evaluating pre-and posttransplant outcomes of foreign 
| PATIENTS AND ME THODS

| Study sample
We conducted a retrospective analysis of adults who were wait- 
| Study outcomes
Waitlist outcomes and posttransplant outcomes were assessed.
Waitlist outcomes included rates of DDLT and removal from the waitlist for death or clinical deterioration ("too sick to transplant").
Posttransplant outcomes included patient survival and lost to follow-up per OPTN/UNOS data. 
| Study covariates
| Statistical analysis
Multivariable logistic regression models were used to evaluate waitlist outcomes. The two waitlist outcomes of interest were DDLT and removal from the waitlist for death (waitlist mortality) or clinical deterioration. Each of the clinical parameters used were first analyzed in univariate models, and only those with a P-value of <0.1 were included in the final model. The final model included patient-level covariates (see above) that were significantly associated with the outcomes (P < .05) and/or confounded the relationship between the citizenship status (exposure) and the outcomes. In order to evaluate transplant outcomes, we fit multivariable competing risk models with the outcome being time-to-lost to follow-up and the competing event being death. Similarly, in models evaluating posttransplant mortality, death was the outcome and lost to follow-up the competing risk. Such models were utilized because death may occur before lost to follow-up and vice versa. Thus, death and lost to follow-up did not represent censoring events, but rather were considered a competing risk.
This study was approved by the institutional review board at the University of Pennsylvania. Data were analyzed using Stata, version 15 (Stata Corp., College Station, TX). 
| RE SULTS
| Waitlist outcomes
In unadjusted analyses, NCNRs were more likely to receive a DDLT and less likely to die or be removed from the waitlist for clinical worsening ( Table 2) . Of those waitlisted for DDLT, 51.8% of USCRs, and 55.5% of NCNRs went on to receive a DDLT whereas 22.7% of USCRs and 17.9% of NCNRs died on the waitlist or were removed for clinical deterioration. The median MELD score and laboratory values at time of removal from the waitlist were not different between the two groups ( Table 2) . In adjusted models, the probability of DDLT was not significantly different among NCNRs and USCRs (P > .5) but
NCNRs were significantly less likely to be removed from the waitlist for death or clinical deterioration (aOR: 0.80, 95% CI: 0.69-0.93, P = .003). Among NCNRs who were waitlisted, there were no significant differences in waitlist outcomes based on the region of listing (P > .05). Our model also showed that the following characteristics (Table 3 ).
| Transplant outcomes
| Lost to follow-up
NCNRs were significantly more likely to be lost to follow-up in both unadjusted and adjusted analyses (Tables 4 and 5 ). In multivariable competing risk models among all LT recipients, NCNRs had an 11-fold higher risk of being lost to follow-up after accounting for the competing risk of death (SHR 11.44, 95% CI: 8.72-15.01, P < .001) ( Table 5 , Figure 2 ). In our model, NCNRs transplanted in regions 4 (SHR 2.33, 95% CI: 1.58-3.45, P < .01) and 5 (SHR 2.18, 95% CI:
1.48-3.19, P < .01) had higher rates of lost to follow-up (Table 5 ), but there was no significant interaction between region and foreigner status (P > .05). There were also no significant differences in the rates of being lost to follow-up based on etiology of liver disease, In univariable analysis, NCNRs were more likely to proceed to DDLT and less likely to die or be removed for clinical deterioration. MELD scores and labs at time of waitlist removal were similar among NCNRs and USCRs. Note: data are given as median (IQR) or n (%). Serum creatinine is listed in mg/dL and serum sodium is listed as mEq/L. 
TA B L E 2
| D ISCUSS I ON
In this retrospective analysis of patients waitlisted for LT, we found that NCNRs had lower rates of waitlist mortality, lower rates of posttransplant mortality, yet markedly higher rates of being lost to follow-up despite similar transplantation rates. Moreover, we found that a disproportionately higher number of NCNR listings were in UNOS regions 3, 5, and 7. In our current era of organ shortage and changes in liver redistribution policies, these findings raise important issues regarding current organ allocation practice and post-LT care expectations. Given that we are practicing in an era of organ shortage, transplant physicians must be judicious, when choosing whom to place on the waitlist for transplantation.
Currently, liver transplantation is based on the severity of disease such that patients with higher MELD scores are ranked higher on the waitlist. Since there are no durable artificial means of replacing liver function (as there is with renal failure in the forms of dialysis), there Rates of DDLT and living donor transplantation, multiorgan transplantation, posttransplant length of hospital stays, and labs at time of transplantation were similar among USCRs and NCNRs. Note, data are given as median (IQR) or n (%). NCNRs had an eleven-fold higher risk of being lost to follow-up after accounting for the competing risk of death. Region as a category was significant, but only region 4 and 5 were significant in pairwise comparisons. There was no significant interaction between region and foreigner status. PSC, primary sclerosis cholangitis. There are several limitations to our study. First of all, the data are self-reported by transplant centers and thus may be invalid.
TA B L E 4 Posttransplant outcomes by donor type
TA B L E 5 Competing risk model for lost to follow-up
Specifically, the citizenship status of patients is categorical (NCNR and NCNRtx) and also not validated. Also, it is well known that waitlist mortality and time to transplantation are not ideal measures of access to transplantation as there are many factors that affect the timing of initial listing. Despite these limitations, though, our study is useful in that it highlights the need for further policy development and sets the stage for further analyses regarding post-LT follow-up of NCNRs.
To our knowledge, transplant outcomes of NCNRs have not been previously explored in the liver transplant community. This is the first study to assess outcomes of NCNRs in comparison to USCRs, and further studies are needed to better assess post-LT outcomes in NCNRs specifically.
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